Cowen reaffirmed their hold rating on shares of Unum Therapeutics (NASDAQ:UMRX) in a report published on Monday.

Separately, Wedbush lifted their price objective on Unum Therapeutics from $18.00 to $20.00 and gave the company an outperform rating in a research note on Tuesday, August 14th.

Shares of NASDAQ:UMRX opened at $11.07 on Monday. Unum Therapeutics has a 12-month low of $10.15 and a 12-month high of $17.66.

Unum Therapeutics (NASDAQ:UMRX) last issued its quarterly earnings results on Monday, August 13th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.02. The business had revenue of $1.67 million during the quarter, compared to analyst estimates of $2.45 million. research analysts predict that Unum Therapeutics will post -1.56 EPS for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp acquired a new position in shares of Unum Therapeutics in the 2nd quarter valued at about $177,000. Cowen Inc. acquired a new position in shares of Unum Therapeutics in the 2nd quarter valued at about $8,341,000. Bank of America Corp DE acquired a new position in shares of Unum Therapeutics in the 2nd quarter valued at about $1,485,000. BlackRock Inc. acquired a new position in shares of Unum Therapeutics in the 2nd quarter valued at about $6,403,000. Finally, Keybank National Association OH acquired a new position in shares of Unum Therapeutics in the 2nd quarter valued at about $195,000. 51.51% of the stock is currently owned by institutional investors and hedge funds.

About Unum Therapeutics

Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma.

Featured Story: How Important is Technical Analysis of Stocks

Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.